Oppenheimer Maintains Outperform on Entrada Therapeutics, Raises Price Target to $23

Benzinga Newsdesk www.benzinga.com Positive 93.5%

Neg 0% Neu 0% Pos 93.5%

Oppenheimer analyst Francois Brisebois maintains Entrada Therapeutics (NASDAQ:TRDA) with a Outperform and raises the price target from $21 to $23.